Comparing Cardax (OTCMKTS:CDXI) & Daiichi Sankyo (OTCMKTS:DSNKY)

Cardax (OTCMKTS:CDXI) and Daiichi Sankyo (OTCMKTS:DSNKY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.

Analyst Ratings

This is a summary of current ratings and target prices for Cardax and Daiichi Sankyo, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardax	0	0	0	0	0.00
Daiichi Sankyo	1	0	0	1	2.50

Given Cardax’s higher possible upside, analysts plainly believe Cardax is more favorable than Daiichi Sankyo.

Volatility and Risk

Cardax has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Daiichi Sankyo has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cardax and Daiichi Sankyo”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardax	N/A	N/A	N/A	N/A	N/A
Daiichi Sankyo	$12.39 billion	2.73	$1.95 billion	$1.09	16.35

Daiichi Sankyo has higher revenue and earnings than Cardax.

Profitability

This table compares Cardax and Daiichi Sankyo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardax	N/A	N/A	N/A
Daiichi Sankyo	14.83%	18.64%	8.53%

Summary

Daiichi Sankyo beats Cardax on 6 of the 8 factors compared between the two stocks.

About Cardax

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.